SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sandu Pharmaceuticals informs about demise of MD

20 Jun 2026 Evaluate
Sandu Pharmaceuticals has informed about sad demise of Umesh Sandu (DIN:01132141), Promoter and Managing Director of the Company, on Friday, 19th June 2026. The Company has immensely benefitted from his vision and active participation in various Committee Meetings and Board Meetings during his tenure. Consequent to his demise he ceases to be Member of Audit Committee and Stakeholders Relationship Committee. Umesh Sandu’s (DIN:01132141) sudden and unexpected demise will be irreparable loss to the Company. The Chairman, and all the Directors and employees of the Company convey deep sympathy, sorrow and condolences to his family members.

The above information is a part of company’s filings submitted to BSE.

Sandu Pharmaceutical Share Price

40.94 -1.20 (-2.85%)
23-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1867.80
Dr. Reddys Labs. 1301.30
Cipla 1433.10
Zydus Lifesciences 1112.10
Lupin 2356.55
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: